Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

88
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
88
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

324
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
324
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

673
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
673
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Drug Therapy01:28

Drug Therapy

155
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
155
Long-term Potentiation01:25

Long-term Potentiation

3.1K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal cognitive outcomes in two progressive supranuclear palsy clinical trials.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Trajectories of brain structure and function in young adult carriers of genetic frontotemporal dementia variants.

medRxiv : the preprint server for health sciences·2026
Same author

Clinical Associations of Cerebrospinal Fluid TMEM106B in Familial and Sporadic Frontotemporal Dementia.

JAMA neurology·2026
Same author

Development and validation of a harmonized memory score for multicenter Alzheimer's disease and related dementia research.

Alzheimer's research & therapy·2026
Same author

The BEYONDD Pilot Study: A Decentralized Community-Engaged Research Framework for Multimodal Characterization of Neurodegenerative Risk in a Multi-Ethnic, Midlife Cohort with Subjective Cognitive or Behavioral Complaints.

medRxiv : the preprint server for health sciences·2026
Same author

Remote, self-administered, smartphone cognitive testing in a registry-based cohort: Feasibility, reliability, and validity findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Mammalian Respiratory Chain Complex Assemblies and Their Links to Mitochondria Stress-Induced Human Diseases.

Advances in experimental medicine and biology·2026
Same journal

Enzyme Assemblies in Nucleotide Metabolism: Structure, Regulation, and Disease Implications.

Advances in experimental medicine and biology·2026
Same journal

The Pyruvate Dehydrogenase Complex: A 90-Year-Old Enigma Shaping the Future of Structural Enzymology.

Advances in experimental medicine and biology·2026
Same journal

Regulation of the Anti-termination RNA Transcription Complex by Lon-Mediated Lambda N Degradation.

Advances in experimental medicine and biology·2026
Same journal

PCNA Macromolecular Complexes: PCNA Serves as a Molecular Hub Regulating Multiple Cellular Processes Inside and Outside of the Nucleus.

Advances in experimental medicine and biology·2026
Same journal

Dynamic Assemblies in Genome Maintenance.

Advances in experimental medicine and biology·2026
See all related articles

Related Experiment Video

Updated: Nov 21, 2025

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields
08:14

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields

Published on: May 4, 2017

15.4K

FTLD Treatment: Current Practice and Future Possibilities.

Peter A Ljubenkov1, Adam L Boxer2

  • 1Memory and Aging Center, Department of Neurology, University of California, San Francisco, USA.

Advances in Experimental Medicine and Biology
|January 12, 2021
PubMed
Summary
This summary is machine-generated.

Frontotemporal dementia (FTD) syndromes, including behavioral variant frontotemporal dementia (bvFTD) and primary progressive aphasia (PPA), are fatal. This review covers current supportive care and explores emerging disease-modifying therapies for FTD.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K
Learning Modern Laryngeal Surgery in a Dissection Laboratory
07:30

Learning Modern Laryngeal Surgery in a Dissection Laboratory

Published on: March 18, 2020

8.5K

Related Experiment Videos

Last Updated: Nov 21, 2025

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields
08:14

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields

Published on: May 4, 2017

15.4K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K
Learning Modern Laryngeal Surgery in a Dissection Laboratory
07:30

Learning Modern Laryngeal Surgery in a Dissection Laboratory

Published on: March 18, 2020

8.5K

Area of Science:

  • Neurology
  • Neuroscience
  • Pathology

Background:

  • Behavioral variant frontotemporal dementia (bvFTD) and primary progressive aphasia (PPA) are progressive, fatal neurodegenerative disorders.
  • These conditions fall under the umbrella of frontotemporal dementia (FTD) syndromes, associated with frontotemporal lobar degeneration (FTLD) pathology.
  • Currently, management focuses on supportive care, with limited disease-modifying treatments available.

Purpose of the Study:

  • To review current therapeutic strategies for patients with bvFTD and PPA.
  • To outline the landscape of potential new disease-modifying therapies for FTD.
  • To emphasize the role of physicians and neurologists in patient/caregiver support and research navigation.

Main Methods:

  • Literature review of current treatment options for bvFTD and PPA.
  • Analysis of emerging therapeutic targets and clinical trials for FTD.
  • Synthesis of information on supportive care frameworks and caregiver support.

Main Results:

  • Supportive treatment frameworks exist for FTD syndromes, focusing on symptom management and caregiver support.
  • Physicians play a crucial role in managing expectations and coordinating care.
  • A growing number of research opportunities, including clinical trials, are available for FTD.

Conclusions:

  • While bvFTD and PPA are fatal, comprehensive supportive care frameworks are established.
  • Physicians and neurologists are key in guiding patients and families through diagnosis, care, and research participation.
  • Future therapeutic strategies aim to modify the disease course by targeting FTLD pathophysiology.